Canada Markets closed

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
32.24-1.11 (-3.33%)
At close: 04:00PM EST
31.50 -0.74 (-2.30%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close33.35
Open33.35
Bid31.20 x 800
Ask32.30 x 1100
Day's Range31.49 - 33.39
52 Week Range19.38 - 87.24
Volume480,551
Avg. Volume853,139
Market Cap1.211B
Beta (5Y Monthly)2.41
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

    Company to host conference call today at 8:00 AM Eastern NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2021. “Over the past several months we have continued to advance our differentiated late-stage CNS product candidates aimed at meaningfully improving the lives of pa

  • GlobeNewswire

    Axsome Therapeutics to Report Third Quarter 2021 Financial Results on November 8, 2021

    Axsome to host conference call and webcast on Monday, November 8, 2021 at 8:00 AM Eastern Time NEW YORK, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter of 2021 on Monday, November 8, 2021 before the opening of the U.S. financial markets. Axsome’s management team will host a

  • GlobeNewswire

    Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million

    $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to increase the size of the facility to $300 million, and the amount immediately available upon U.S. Food